New Data on RTH258 Show Promise New Data on RTH258 Show Promise
A recent phase 1/2 trial shows that RTH258 is a promising alternative to ranibizumab for the treatment of neovascular age-related macular degeneration.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2016 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

New Batches of Ranibizumab Biosimilar Safe, Effective New Batches of Ranibizumab Biosimilar Safe, Effective
Razumab, an Indian biosimilar for ranibizumab, appears to have overcome the high incidence of inflammation with a new manufacturing process, report investigators.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Ranibizumab T & amp;E cost effective for wet AMD in UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2016 Category: Drugs & Pharmacology Source Type: news

Doc's Dilemma: Lucentis or Avastin?
(MedPage Today) -- A physician weighs the risks and benefits (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 28, 2016 Category: American Health Source Type: news

Eye drug safety: the impact of a Cochrane Review comparing two treatments for macular degeneration
For more than 20 years, Cochrane has produced systematic reviews of primary research in human health care and health policy. We are internationally recognized as the highest standard in evidence-based healthcare resources.The fourth video in the Cochrane Making a Difference series focuses on the Cochrane Review 'Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration', published in September 2014 from the Cochrane Eyes & Vision Group. The review found that the systemic safety of bevacizumab for macular degeneration appears to be similar to that of ranibizumab - an important co...
Source: Cochrane News and Events - July 1, 2016 Category: Information Technology Authors: nowens at cochrane.org Source Type: news

Aflibercept, ranibizumab are not cost effective in DME
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2016 Category: Drugs & Pharmacology Source Type: news

Industry Incentives May Drive Pricier Anti-VEGF Drug UseIndustry Incentives May Drive Pricier Anti-VEGF Drug Use
Ophthalmologists with the most and largest payments had highest rates of injection with aflibercept and ranibizumab. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Two Expensive Diabetic Macular Edema Drugs Not Cost-effectiveTwo Expensive Diabetic Macular Edema Drugs Not Cost-effective
Anti-VEGF medicines aflibercept and ranibizumab would have to drop in price by 69% and 80%, respectively, to be worth the societal cost compared with bevacizumab, a new study has found. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

High-priced drugs used to treat diabetic macular edema not cost-effective
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 9, 2016 Category: Science Source Type: news

Newer Drugs Helping Older People With Eye Disease
FRIDAY, May 20, 2016 -- New medications are boosting quality of life for many older people with age-related macular degeneration (AMD), a new study indicates. The drugs Avastin and Lucentis have significantly increased the number of people with AMD... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 20, 2016 Category: Journals (General) Source Type: news

Long-term benefits of age-related macular degeneration treatments
A 5-year follow-up study confirmed the long-term benefits of using the drugs Avastin and Lucentis to treat age-related macular degeneration. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - May 9, 2016 Category: Consumer Health News Source Type: news

Age-related macular degeneration before and after the era of anti-VEGF drugs
NIH-funded study of Avastin and Lucentis examines their effects at five years. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 3, 2016 Category: American Health Source Type: news

Many With Wet AMD Need Ranibizumab Retreatment Even After Year-Long PauseMany With Wet AMD Need Ranibizumab Retreatment Even After Year-Long Pause
Retreatment with ranibizumab is necessary for up to a third of neovascular age-related macular degeneration (AMD) patients who are treatment-free for one year, new research shows. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 27, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Delayed Visual Improvements in AMD Continue With Ranibizumab TreatmentDelayed Visual Improvements in AMD Continue With Ranibizumab Treatment
Visual improvements in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab continue after macular edema resolves, researchers report. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 30, 2016 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Aflibercept for Macular Edema Secondary to Central RVOAflibercept for Macular Edema Secondary to Central RVO
Aflibercept may be an effective therapeutic option for macular edema due to central retinal vein occlusion that did not respond to treatment with bevacizumab or ranibizumab. Eye (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2016 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news